Form 4: Fortress Biotech Boosts ATXI Stake with Dividend Shares

Fortress Biotech, a 10% owner and director, increased its beneficial ownership in Avenue Therapeutics by 111,209 shares of common stock as an annual dividend.

Summary

• Fortress Biotech, Inc. (Reporting Person), a Director and 10% Owner of Avenue Therapeutics, Inc. (ATXI), acquired 111,209 shares of ATXI common stock.
• The transaction occurred on January 2, 2026.
• These shares were granted as the 2025 annual dividend on Fortress Biotech's Class A Preferred Stock, calculated as 2.5% of Avenue Therapeutics' fully diluted outstanding capitalization on December 31.
• Following this transaction, Fortress Biotech beneficially owns a total of 439,733 shares of Avenue Therapeutics common stock.
• The shares were acquired at a price of $0, consistent with a dividend grant.

Sentiment

Score: 7

Explanation: The filing reports a routine dividend distribution to a significant shareholder and director, increasing their beneficial ownership. While not an open market purchase, it reflects a pre-existing financial arrangement and adds to insider holdings, which is generally viewed as a neutral to slightly positive signal.

Positives

• A significant shareholder and director, Fortress Biotech, increased its stake in Avenue Therapeutics, potentially signaling confidence in the company's future.
• The acquisition of 111,209 shares at a $0 price indicates a dividend distribution, which is a return to preferred shareholders.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

Insider transactions, such as those reported on Form 4, are closely watched by investors as they can provide insights into the confidence levels of a company's directors and significant shareholders. An increase in ownership by a 10% owner and director, even through a dividend, can be interpreted as a positive signal regarding the company's long-term prospects, especially in the biotech sector where strategic alliances and significant shareholder backing are crucial.

Comparison to Industry Standards

• This filing reports a routine dividend distribution to a preferred shareholder, which is a standard corporate finance practice. There are no specific comparable companies, projects, or results mentioned in this Form 4 to assess against industry benchmarks.

Related Party Transactions

• The acquisition of shares by Fortress Biotech, Inc., a 10% owner and Director of Avenue Therapeutics, Inc., as an annual dividend on preferred stock, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The increase in beneficial ownership by a significant shareholder (Fortress Biotech) could be viewed positively, potentially signaling confidence. However, the issuance of new shares for a dividend could lead to minor dilution for common shareholders, though this is typically accounted for in preferred stock terms.
• Preferred Shareholders (Fortress Biotech): This transaction represents the receipt of their expected annual dividend, fulfilling the terms of their preferred stock agreement.

Key Dates

Recommendation

This Form 4 reports a routine, pre-arranged dividend distribution to a significant insider. While an increase in insider ownership is generally a positive signal, this specific transaction is not an open market purchase reflecting new investment conviction but rather the fulfillment of a preferred stock agreement. Therefore, it doesn't provide a strong catalyst for a "buy" or "sell" recommendation but reinforces a "hold" for existing investors, acknowledging the continued involvement of a major stakeholder.

Keywords

Fortress Biotech, Avenue Therapeutics, ATXI, SEC Form 4, Insider Transaction, Beneficial Ownership, Common Stock, Dividend, 10% Owner, Director